Back to Journals

Journal of Hepatocellular Carcinoma


Dr Kaseb

Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, United States

Dr Kaseb

Editor-in-Chief: Dr. Ahmed Kaseb

Dr. Ahmed Kaseb is a Professor and Program Director of Hepatocellular Carcinoma (HCC), in the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Dr. Kaseb received his medical degree from Cairo University, and worked as a research fellow at University of Michigan, in Ann Arbor for two years focusing on cancer biomarkers before starting Internal Medicine Residency at Wayne State University, in Detroit, Michigan where he excelled in clinical training and was the recipient of The Best Resident Award in 2003-2004. He then finished Medical oncology fellowship at Henry Ford Hospital, in Detroit, Michigan where he continued his translational research work which led to three major publications presenting circulating biomarkers for early cancer detection in the area of bladder and prostate cancers and his work on HCC biomarkers was subsequently initiated. Dr. Kaseb’s work received international awards from the American Society of Clinical Oncology (ASCO) an American College of Physicians (ACP).

Dr. Kaseb joined the department of Gastrointestinal Medical Oncology, at the University of Texas MD Anderson Cancer Center in 2007 to lead the HCC program. Dr. Kaseb is heavily involved in HCC clinical research where he has served as principal investigator on multiple clinical trials. Dr. Kaseb’s principal research interests include HCC systemic and multi-disciplinary therapies, in addition to molecular staging studies. His research also examines the differential effects of demographics and hepatitis status on treatment outcome in HCC. Based on his interest and research, he has developed several protocols in the treatment and staging of HCC. His published studies have yielded impressive results. Dr. Kaseb’s work has contributed greatly to the understanding of HCC interdisciplinary therapies and molecular staging, and has received governmental and pharmaceutical funding for several projects and clinical trials.

Dr. Kaseb has extensively authored and co-authored dozens of papers and books. Dr. Kaseb serves as an Editor and Scientific Reviewer for several international medical journals, and has received several national and international awards throughout his career. He is an active member of several international societies and has served on several committees and advisory boards at the national and international levels, and has participated in several international expert consensus conferences in the area of HCC.


Dr Dawson

Department of Radiation Oncology, University of Toronto, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Dr Dawson

Associate Editor: Dr Laura Dawson

Laura Dawson is a Professor in the Department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist at the Radiation Medicine Program, Princess Margaret Cancer Centre, in Toronto. She is an internationally recognized leader in hepatocellular carcinoma and in oligo-metastases. Her research has primarily focused on implementation of advanced radiation technologies (e.g. stereotactic body radiation therapy (SBRT), advanced imaging and image guidance) to improve outcomes and to reduce the risk of toxicity in patients with liver cancer. She is the principal investigator of two randomized phase III clinical trials investigating the use of radiation therapy in hepatocellular carcinoma (RTOG1112 and CCTG HE1), and she has led local investigator SBRT combined modality trials hepatocellular carcinoma patients. Dr. Dawson has published over 200 scientific papers and has mentored over 50 students from around the world. She has received numerous awards for her teaching, research and impact in oncology.


Professor Furuse

Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, Japan

Professor Furuse

Associate Editor: Junji Furuse

Dr. Junji Furuse is a Professor in the Department of Medical Oncology, Kyorin University School of Medicine, Japan.

In 1984 Dr. Furuse graduated from Chiba University of Medical School and then joined the First Department of Internal Medicine, Chiba University. In 1992 he moved to the Department of Hepatobiliary and Pancreatic Medical Oncology at the National Cancer Center Hospital East, Chiba, Japan until 2008 when he began his current role.

Dr. Furuse is Chair of the Hepatobiliary and Pancreatic Oncology Group for the Japanese Clinical Oncology Group (JCOG). He is Director of the Japanese Society of Medical Oncology (JSMO) and the Director and Chair of the health insurance committee for the Japanese Pancreas Society (JPS). He is also on the council of the International Association of Pancreatology.

Dr. Furuse specializes in gastrointestinal medical oncology, especially hepatobiliary and pancreatic cancer.


Dr Hassan

Department of Epidemiology, University of Texas, MD Anderson Cancer Center, United States

Dr Hassan

Associate Editor: Dr Manal Hassan

Dr. Hassan is trained to become a physician with master and Doctor of Philosophy degrees in public health and epidemiology from University of Texas. Since joining The University of Texas M.D. Anderson Cancer center, Dr. Hassan has focused her research on the molecular epidemiology of hepatobiliary cancers in the US, with an emphasis on investigating new risk factors and biomarkers for early detection and cancer prevention. She specifically highlighted the impact of obesity on the risk and clinical outcome of rare cancers including liver cancer, pancreatic cancer, adrenocortical cancer, and neuroendocrine cancer. Dr. Hassan has been involved in several educational activities and served on the advisory committee for many graduate students. She has also been engaged in the reviewing panels of high impact journals and research funding agencies. She earned several awards from the National Cancer Institute where she has collaborated extensively with investigators inside and outside USA in several translational researches yielding many high impact publications in the field of cancer epidemiology. Currently, she is leading a national consortium to study the epidemiology of liver cancers in North America.


Dr Murthy

Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, United States

Dr Murthy

Associate Editor: Ravi Murthy

Ravi Murthy is a Professor of Interventional Radiology (IR), in the Division of Diagnostic Imaging, Department of Interventional Radiology at the University of Texas MD Anderson Cancer Center, Houston, Texas USA.

Dr. Murthy received his medical degree from St. John’s Medical College & Hospital in Bangalore University, Bangalore, India.  He completed his Clinical Residencies in Internal Medicine at Robert Wood Johnson University Hospital in New Brunswick, NJ and Diagnostic Radiology at Morristown Memorial Hospital, Columbia Presbyterian College of Physicians & Surgeons, Morristown, NJ where he also served as Chief Resident. He completed his Clinical Fellowship in Vascular & Interventional Radiology, University Medical Center, Stony Brook, NY and American College of Radiology Information Network (ACRIN) Research Fellowship under the purview of Radiological Society of North America.

Dr. Murthy is ABIM certified in Internal Medicine, Diagnostic Radiology with CAQ in Vascular & Interventional Radiology.  He has received various honors and awards such as Castle Connolly Top Doctor and Distinguished Reviewer Award for the Journal of Vascular and Interventional Radiology and is Fellow of the American College of Physicians.

Dr. Murthy has authored and co-authored numerous papers, books and articles and has received numerous national and international awards throughout his career.  He is an active member of several societies and serves on several committees and advisory boards at the national and international levels

His research interests include Yttrium-90 microspheres for hepatic malignancies and image guided interventional trials.
 


Professor Waked

Department of Hepatology, National Liver Institute, Menofia University, Egypt

Professor Waked

Associate Editor: Dr Imam Waked

Imam Waked is Professor of Medicine in the department of Hepatology, past Chair Hepatology and Dean Emeritus of the National Liver Institute in Egypt. Dr Waked graduated Cairo University School of Medicine, joined the National Liver Institute in 1986, obtained a Doctorate degree from Ain Shams University in Cairo in 1992, and trained in the liver unit of the University of Southern California in Los Angeles. He is a Fellow of the American Association of the Study of Liver Disease (FAASLD), and a Fellow of the Royal College of Physicians (FRCP) in London.
Dr. Waked has more than 100 peer-reviewed publications in international journals. He currently heads the clinical trial unit in the National Liver Institute. His research has focused on hepatitis C and hepatocellular carcinoma epidemiology and treatment. He is a board member of the Egyptian National Committee for Control of Viral Hepatitis which oversees the National Hepatitis C Treatment and Screening Program and is a member of the technical advisory board of the Coalition for Global Hepatitis Elimination.


Dr Wang

Laboratory of Human Carcinogenesis, National Cancer Institute, United States

Dr Wang

Associate Editor: Xin Wang

Dr. Wang is a Senior Investigator at the National Cancer Institute (NCI) where he oversees a basic/translational research program emphasizing new molecular approaches to define tumor subtypes and identify biomarkers for early detection, diagnosis, prognosis and prediction, to delineate the molecular mechanisms of liver cancer with applications towards precision medicine. Dr. Wang received his PhD training from New York University School of Medicine and further research training from Roche Institute of Molecular Biology and NCI. Currently, he also serves as Chief of the Liver Carcinogenesis Section and Deputy Chief of the Laboratory of Human Carcinogenesis, Center for Cancer Research at NCI. He is a world renowned liver cancer researcher with a special focus on cancer functional genomics. His lab utilizes state-of-the-art technologies to study liver cancer and other human malignancies. He leads several major international research initiatives on liver cancer genomics and clinical studies through collaborations with multiple universities and cancer centers. He is Honorary Professor of Fudan University and a recipient of several NIH Director’s Awards and NCI Director’s Awards for his outstanding scientific achievement in liver cancer research. He also is a recipient of the NCI Mentor’s Award for excellence in mentoring and guiding the careers of trainees in cancer research and Blue Faery Award for excellence in liver cancer research.  


Editorial Board

Stephen J. Beebe, Professor, Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA, USA

Srikanta Dash, Professor, Director of Hepatitis Research Laboratory, Department of Pathology and Laboratory Medicine, Gastroenterology and Hepatology, Tulane University Health Sciences Center, New Orleans, LA, USA

Aldo Dettino, Professor in Clinical Oncology and Translational Research, Department of Clinical Oncology, A. C. Camargo Cancer Center, Sao Paulo-SP, Brazil.

Dan G. Duda, DMD, PhD, Director of Translational Research in GI Radiation Oncology, Investigator, Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Associate Professor of Tumor Biology, Harvard Medical School, Charlestown, MA, USA.

Tamer El-Baz, Professor, Department of Endemic Medicine and Hepatology, Cairo University Hospital, Egypt.

Prof. Hesham Elghazaly , Professor of Clinical Oncology, Head of Medical Research Center MASRI, Ain Shams University, Cairo, Egypt.

Khaled Elsayes, Professor of Diagnostic Radiology, University of Texas MD Anderson Cancer Center and the Medical School of University Texas in Houston, USA

Catherine Frenette, Medical Director of Liver Transplantation, Scripps Center for Organ Transplantation, Director of the Liver and Hepatocellular Cancer Program, Scripps MD Anderson Cancer Center, Scripps Green Hospital, La Jolla, CA, USA.

David Gerber, Professor and Division Chief, Division of Transplantation, Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, USA

Heping Hu, Director and Professor, Department of Heptobiliary Diseases, Eastern Hepatobiliary Hospital, Shanghai, People's Republic of China

Do Young Kim, Associate Professor in Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

PPhilippe Merle, M.D., Ph.D., Professor of Hepato-Gastroenterology and Digestive Oncology, and UMR INSERM 1052, Epigenetics and Epigenomics of Hepatocellular Carcinoma (EpiHep), Centre of Research in Cancerology, Lyon University and Croix-Rousse Hospital, Lyon, France.

Dr Ganesh Nagarajan, Consultant Surgeon Hepatobiliary Pancreatic, GI oncology & Liver Transplant, P D Hinduja Hospital, Mumbai, India.

Ashraf Omar MD, Professor Hepatology & Liver Transplantation, Head Liver Cancer Clinic, Cairo University, President of Egyptian Society of liver cancer, Head of MENA NCCN Committee of HCC, Egypt. 

Tushar Patel, Professor of Medicine, Mayo Clinic College of Medicine, Jacksonville, FL, USA

Lorenza Rimassa, Associate Professor of Medical Oncology, Director of the Residency Program in Medical Oncology, Department of Biomedical Sciences, Humanitas University. Deputy Director, Medical Oncology Unit, Head GI Cancer Section, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.

Rodolfo Sacco, Director of Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital Medical School, Foggia, Italy.

Toshihito Seki, Professor and Director, Liver disease center, Kansai Medical University Medical Center, Osaka, Japan.

Mohamed Kamal ElDin Aly Fahmy Shaker, President of the Egyptian Society for Liver Cancer; Member of the Supreme Committee of Hepatology Health Insurance Organisation; Emeritus Professor of Tropical Medicine and Hepatology Ain Shams University, Cairo, Egypt

Ming Shi, Professor, Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, People's Republic of China

Oliver Stoeltzing, Head Doctor, Zentrum für Allgemein- und Viszeralchirurgie Riesa-Meißen, Elblandkliniken, Meißen, Germany.

Janio Szklaruk, Doctor, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, USA.

Hua Tang, Professor of Molecular Biology & Microbiology, School of Basic Medical Sciences, Tianjin Medical University, People's Republic of China

Harrys A. Torres, MD, FACP, FIDSA, Professor of Medicine; Founding Director of Hepatitis C Clinic; Medical Director of Internal Medicine Center, Department of Infectious Diseases, Infection Control and Employee Health; Adjunct Professor, Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Hop S. Tran Cao, MD, FACS, Associate Professor of Surgery, Hepato-Pancreato-Biliary Section, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center.

Joerg Trojan, Professor of Medicine, Gastrointestinal Oncology, Goethe-University Medical Center, Frankfurt, Germany

Jia-Sheng Wang, Professor and Head, Department of Environmental Health Science, College of Public Health, The University of Georgia, Athens, GA, USA

Chia-Jui Weng received his PhD at Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan. He was the Lead Guest Editor of BioMed Research International and Guest Editor of Evidence-Based Complementary and Alternative Medicine (eCAM) Journal. He was the organizing Committee member of 6th International Conference on Nutrition and Physical Activity (NAPA2015) and Chair of session in international conferences.